Literature DB >> 28382502

Economic evaluation of personalized medicine: a call for real-world data.

Robert Terkola1,2, Fernando Antoñanzas3, Maarten Postma2,4,5.   

Abstract

Mesh：

Year:  2017        PMID： 28382502     DOI： 10.1007/s10198-017-0890-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  9 in total

1.  Pharmacogenomics, evidence, and the role of payers.

Authors:  P A Deverka
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

2.  Current methodological issues in the economic assessment of personalized medicine.

Authors:  Lieven Annemans; Ken Redekop; Katherine Payne
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

Review 3.  Economic opportunities and challenges for pharmacogenomics.

Authors:  Patricia A Deverka; John Vernon; Howard L McLeod
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

4.  Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.

Authors:  Maarten J Postma; Cornelis Boersma; Dominique Vandijck; Stefan Vegter; Hoa H Le; Lieven Annemans
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-08       Impact factor: 2.217

5.  Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

Authors:  Eric Faulkner; Lieven Annemans; Lou Garrison; Mark Helfand; Anke-Peggy Holtorf; John Hornberger; Dyfrig Hughes; Tracy Li; Daniel Malone; Katherine Payne; Uwe Siebert; Adrian Towse; David Veenstra; John Watkins
Journal:  Value Health       Date:  2012-09-07       Impact factor: 5.725

Review 6.  The Value of Medicines: A Crucial but Vague Concept.

Authors:  Fernando Antoñanzas; Robert Terkola; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

7.  Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.

Authors:  John C O'Donnell
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

Review 8.  Is individualized medicine more cost-effective? A systematic review.

Authors:  Maximilian H M Hatz; Katharina Schremser; Wolf H Rogowski
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981

Review 9.  Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine.

Authors:  Ildar Akhmetov; Rostyslav V Bubnov
Journal:  EPMA J       Date:  2015-09-30       Impact factor: 6.543
  9 in total
  3 in total

1.  Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis.

Authors:  Z Kevin Lu; Xiaomo Xiong; Taiying Lee; Jun Wu; Jing Yuan; Bin Jiang
Journal:  Front Pharmacol       Date:  2021-10-19       Impact factor: 5.810

2.  Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.

Authors:  Martin Vu; Koen Degeling; Ella R Thompson; Piers Blombery; David Westerman; Maarten J IJzerman
Journal:  Eur J Haematol       Date:  2022-03-02       Impact factor: 3.674

3.  Cost-effectiveness of precision medicine: a scoping review.

Authors:  Miriam Kasztura; Aude Richard; Nefti-Eboni Bempong; Dejan Loncar; Antoine Flahault
Journal:  Int J Public Health       Date:  2019-11-15       Impact factor: 3.380
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.